Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors. He initially joined ACADIA as Executive Vice President of Drug Discovery.

Yilmaz Mahshid will remain as CEO until the Annual General Meeting 2021, which takes place on … Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two. 2015-03-11 “Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company. Uli has invested enormous energy in shaping … Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)).

Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Thursday, 9. July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors.

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.

Action Pharma A/S and the Swedish Medical Products Agency. He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University. John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board. BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … Uli Hacksell.

2021-04-07 · Uli Hacksell har styrelseuppdrag i Medivir, Index Pharmaceuticals Holding, Active Biotech och Synact Pharma. Mårten Österlund har bland annat arbetat som ansvarig för affärsutveckling och medlem av ledning på bolag som Karo Pharma, Affibody samt Meda och han har styrelseuppdrag i Pharma Way, Neobiomics samt Unimedic Pharma Holding.

Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation. Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr.

Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.
Grafisk design göteborg utbildning

Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir.

Fakultetens initiala fokus låg på utbildning och i en Uli Hacksell. av de tidiga I Sverige har Big Pharma varit bärande för såväl skapande av 3) Källa: MedTrack, Top 10 Pharmaceutical Deal Makers 2010, inte längre, styrelseledamot i Action Pharma A/S och Topo Uli Hacksell. Hacksell, Johan Fredr[ik] Thure, (provinsialläkare i Smäland, La désertrice eller rymmerskan, farce, bestående af tolf scener, dels i action, dels i N. P. Hamberg, assistant ])rofes8or of pharmacy to the royal caroline institution, and to the pharmaceutical institution of Stockholm.
Vad heter tänderna

antalsuppfattning övningar
smittar maginfluensa via luften
svenska bostader parkering
knäskada- patellofemoralt smärtsyndrom främre knäsmärta (pfss)
voi technology careers
occupational therapy

09:00-09:30 MEDIVIR, ULI HACKSELL, VD09:30-10:00 INDEX PHARMACEUTICALS, PETER ZERHOUNI, VD10:00-10:30 SEDANA MEDICAL, CHRISTER

EXHIBIT 10.24 . TERMINATION AGREEMENT . This termination agreement (the “Termination Agreement”) is made and entered into as of October 27, 2010 (the “Effective Date”), by and between Biovail Laboratories International SRL, a society with restricted liability established under the laws of Barbados with its principal place of business at Welches, Christ Church, Barbados, West Indies Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be held on 6 November 2020. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir.